Gain Therapeutics Inc. (GANX)$1.78

Market Cap: 56.41 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Gain Therapeutics Inc. (GANX).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-1.9x

EV/FCF, N/A FCF yield

Quality

-106.3%

ROIC, N/A FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 6.6x current ratio

Superinvestors

Top: David Einhorn (0.0%)

Strengths to research

Debt/equity looks manageable at 0.0x.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 6 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for GANX.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


GANX Target	Gain Therapeutics Inc.	$56.4M	-2.9x	-1.9x	-106.3%	N/A	N/A	N/A	N/A	N/A
PEPG	Pepgen Inc	$47.1M	-0.7x	0.2x	-60.8%	N/A	N/A	N/A	N/A	N/A
IVVD	Invivyd Inc.	$69.0M	-3.7x	2.7x	-21.7%	N/A	-109.1%	N/A	N/A	N/A
GUTS	Fractyl Health Inc	$79.8M	-0.5x	0.0x	-1490.3%	N/A	N/A	N/A	N/A	N/A
CRBU	Caribou Biosciences Inc.	$79.9M	-1.3x	-0.6x	-121.2%	-2.0%	-1006.8%	N/A	N/A	N/A
COYA	Coya Therapeutics Inc	$107.2M	-3.8x	-5.6x	-49.3%	N/A	-135.2%	N/A	N/A	N/A
CRIS	Curis Inc.	$25.6M	-0.9x	-0.8x	-138.8%	-2.7%	-288.1%	N/A	N/A	N/A
CGEN	Compugen Ltd	$128.1M	7.4x	1.2x	34.4%	105.2%	43.1%	87.3%	-2.8x	N/A
DMAC	DiaMedica Therapeutics Inc.	$171.4M	N/A	-5.4x	-58.4%	N/A	N/A	N/A	N/A	N/A

Financial Charts

No financial data available for GANX (annual).

1 superinvestors own GANX

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
David Einhorn Greenlight Capital	566,130	$1M	0.03%	0.0%